Please assess the completion status of the following clinical trial:

Trial Title: Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Newly Diagnosed Subjects~* The subject is male or female, aged 18 years of age or older~* The subject has a diagnosis of acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML); the subject must have a pathology-confirmed diagnosis~* The subject must have a pathology-confirmed diagnosis~* Acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML) is defined as having \>25% blasts in the bone marrow and/or peripheral blood~* The subject has not received any chemotherapy or treatment for their acute leukemia prior to the initial study visit~* The subject is able and willing to provide written informed consent~* The subject is able to understand the study and cooperate with all study instructions~Relapsed Subjects~* The subject is male or female, aged 18 years of age or older~* The subject has a diagnosis of relapsed acute lymphocytic leukemia (ALL) or relapsed acute myelogenous leukemia (AML)~* The subject must have a pathology-confirmed diagnosis~* Acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML) is defined as having ≥ 25% blasts in the bone marrow and/or peripheral blood~* The subject has received one or more of the pre-identified chemotherapeutic agents for treatment of their initial acute leukemia diagnosis~* The subject has not received any systemic chemotherapy or treatment for their relapsed acute leukemia~* Receipt of intrathecal chemotherapy will be permissible~* The subject is able and willing to provide written informed consent~* The subject is able to understand the study and cooperate with all study instructions~Exclusion Criteria:~* The subject has an uncontrolled serious medical or psychiatric illness that, in the opinion of the investigator, would compromise the subject's safety or collection of data~* The subject received treatment with an investigational drug within two weeks of the initial or subsequent study visits~* Subjects under the age of 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).